[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hematopoietic-cell-transplant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hematopoietic-cell-transplant":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,60,86,108,135,167,189,211],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100648062","the-medmemos-study-promoting-adherence-to-medications-in-pediatric-bone-marrow-transplant-patients-100648062",false,"NCT07718204","The MedMemos Study: Promoting Adherence to Medications in Pediatric Bone Marrow Transplant Patients","MedMemos: An Intervention to Promote Medication Adherence in Pediatric Allogenic Hematopoietic Stem Cell Transplantation","MedMemos","Inclusion Criteria:\n\n* Child had a Pediatric Allogeneic Hematopoietic Cell Transplant (PAHCT)\n* Child is 0-12 years of age\n* At the time of recruitment child is still in the hospital for PAHCT\n* Child's primary caregiver is responsible for administering medical care and is willing to give consent to participate\n* Child is prescribed an oral medication regimen at discharge\n\nExclusion Criteria:\n\n* Caregiver does not speak English, Spanish, or Arabic\n* Caregiver is not available to provide written permission for the child's participation\n* EMR or medical team report of the caregiver's cognitive status precludes completion of questionnaires\n* The child's medical status or condition precludes completion of the study questionnaires as determined by the physician or caregiver\n* Caregiver is unwilling to store medication in an electronic monitor","ALL","0 Years","12 Years",{"count":21,"type":22},25,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to test the MedMemos Intervention with parents and children who have received a bone marrow transplant. The main study questions are:\n\n* Is the MedMemos intervention acceptable to patients and families?\n* Is the MedMemos intervention feasible for patients, families, and healthcare providers?\n* Does MedMemos help patients and families take their medications better?\n\nParticipants will be asked to complete surveys, attend 4 intervention sessions, and use an electronic box or pill bottle to store their medications in.",[28],"Hematopoietic Cell Transplant",[30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46],"Hematopoietic Cell Transplantation","Bone Marrow Transplant","Pediatric","Cancer","Bone Marrow Failure","Adherence","Medication Adherence","Non-Adherence","Adherence Promotion Intervention","Immunosuppressant","Transition to Outpatient","Managing Medication Regimens","Child","Caregiver","Parent","GVHD","Infection","RECRUITING","2026-07-17",{"date":50,"type":51},"2026-07-21","ACTUAL",{"date":53,"type":51},"2026-05-01",{"date":55,"type":22},"2028-12-31",{"name":57,"class":58},"Nationwide Children's Hospital","OTHER",1,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":17,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":71,"studyType":72,"phases":4,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":59},"100638459","a-novel-conditioning-regimen-for-haplo-hsct-in-older-patients-with-saa-100638459","NCT07586735","A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA","A Novel Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplant in Patients Aged ≥ 40 Years Old With Severe Aplastic Anemia: a Multicenter, Single-arm, Observational Clinical Trial","Inclusion Criteria:\n\n* Severe aplastic anemia;\n* Aged 40-60 years old;\n* Weight 45Kg-100Kg;\n* Eastern Cooperative Oncology Group (ECOG) score ≤3;\n* No major organ injury (ECG ejection fraction \\>45%; bilirubin \\\u003C 2 times the upper limit of normal value; AST and ALT \\\u003C 3 times the upper limit of normal value; serum creatinine \\\u003C 2 times the upper limit of normal value);\n* No severe infection;\n* Subjects voluntarily participated in this clinical trial and signed the informed consent.\n\nExclusion Criteria:\n\n* With other hematologic diseases;\n* Expected survival of less than 1 month;\n* Previous autologous or allogeneic hematopoietic stem cell transplantation;\n* Pregnant patients;\n* Patients with severe mental or neurological disorders that would affect the ability to provide informed consent and\u002For to report or observe adverse events;\n* Other conditions that the investigator determines to be inappropriate for enrollment.\n* Current or recent (\\\u003C4 weeks prior to screening) clinically serious viral, bacterial, fungal, or parasitic infection\n* A history of symptomatic herpes zoster infection within 12 weeks prior to screening\n* Active or chronic viral infection from hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)\n* Have evidence of active tuberculosis (TB), or have previously had evidence of active TB and did not receive appropriate and documented treatment, or have had household contact with a person with active TB and did not receive appropriate and documented prophylaxis for TB\n* Exposure to a live vaccine within 12 weeks prior to enrollment or expected to receive a live vaccine during the study\n* Clinically significant thrombotic event within 24 weeks of screening or are on anticoagulants and in the opinion of the investigator are not well controlled\n* Myocardial infarction (MI), unstable ischemic heart disease, stroke, or New York Heart Association Stage IV heart failure\n* A history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, neurological, or neuropsychiatric disorders or any other serious and\u002For unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking investigational product or interfere with the interpretation of data\n* Any of the following specific abnormalities on screening laboratory tests:\n\n  1. ALT or AST \\>2 x ULN, or total bilirubin ≥1.5 x ULN\n  2. hemoglobin \\\u003C9 g\u002FdL, or total white blood cell (WBC) count \\\u003C2,500\u002FµL, or neutropenia (absolute neutrophil count \\\u003C1,200\u002FµL), or lymphopenia (lymphocyte count \\\u003C750\u002FµL)\n  3. eGFR \\\u003C50 mL\u002Fmin\u002F1.73 m2","40 Years","60 Years",{"count":70,"type":22},64,"2 Years","OBSERVATIONAL","The goal of this prospective, multicenter, single arm observational study is to evaluate the efficacy and safety of the BFCA regimen in ≥ 40 years old SAA patients undergoing haplo-HSCT.",[75,76,28],"Severe Aplastic Anemia","Aplastic Anaemia","2026-07-01",{"date":79,"type":51},"2026-07-06",{"date":81,"type":22},"2026-06",{"date":83,"type":22},"2029-12-30",{"name":85,"class":58},"Peking University People's Hospital",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":92,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":59},"100565259","the-use-of-cytomegalovirus-cell-mediated-immunity-to-optimize-the-duration-of-letermovir-prophylaxis-in-hematopoietic-cell-transplant-recipients-100565259","NCT06639854","The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients","Inclusion criteria\n\n1. Allogeneic HCT recipients with positive CMV serostatus\n2. On letermovir prophylaxis at day 90 post transplant (+\u002F- 7 days)\n3. At high risk for CMV reactivation after day +100:\n\n   1. Prior or active graft versus host disease requiring systemic steroids\n   2. Mismatch stem cell donor (includes haploidentical, mismatch unrelated donor (MMUD), match related donor with at least one mismatch at one of the three specified HLA gene loci (HLA-A, HLA-B, or HLA-DR) and cord donor recipients)\n   3. Received T cell depletion or anti thymoglobulin during conditioning\n   4. CMV reactivation prior to day 100 post transplant\n   5. On steroids at any dose within 2 weeks of enrollment\n\nExclusion criteria\n\n1. Patients under the age of 18\n2. Patients are discharged from our institution and unwilling to come back for follow up\n3. Patients are actively undergoing treatment for CS-CMVi at time of screening. Prior CS-CMVi is not an exclusion from study.\n4. Patients are allergic or intolerant to letermovir or have history of letermovir resistant CMV infection.\n5. Not able to procure letermovir for extended prophylaxis beyond day +100.","18 Years",{"count":94,"type":22},105,[25],"The goal of this laboratory research study is to learn if interrupting a patient's letermovir dosing based on their immune system response can help HSC transplant patients avoid post-treatment CMV infections better than taking letermovir every day without interruption.",[98,28],"Cytomegalovirus Cell Mediated Immunity","2026-06-12",{"date":101,"type":51},"2026-06-15",{"date":103,"type":51},"2024-11-20",{"date":105,"type":22},"2027-12-31",{"name":107,"class":58},"M.D. Anderson Cancer Center",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":92,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":59},"100568102","feasibility-and-acceptability-of-primary-palliative-care-intervention-in-patients-undergoing-hematopoietic-stem-cell-transplantation-100568102","NCT06676852","Feasibility and Acceptability of Primary Palliative Care Intervention in Patients Undergoing Hematopoietic Stem Cell Transplantation","Primary PC HCT","Inclusion Criteria:\n\n* Age 18 years or older\n* Undergoing autologous or allogeneic HCT at MGH\n\nExclusion Criteria:\n\n* Prior receipt of inpatient specialty palliative care on two prior admissions in the past 6 months.\n* Significant uncontrolled psychiatric disorders (psychotic disorder, bipolar disorder, major depression) or other co-morbid disease (dementia, cognitive impairment), which the primary oncologist believes prohibits informed consent or ability to participate in study procedures\n* Inability to comprehend English as this is a preliminary\u002Fpilot study",{"count":116,"type":22},40,[25],"Primary PC - or training HCT clinicians to deliver PC domains as part of routine practice - is an alternative model of supportive care. We have developed Sentinel, a primary PC intervention for HCT clinicians and patients. This study will assess Sentinel's feasibility and acceptability.",[28,120],"Hematologic Malignancy",[122,123,124,125],"palliative care","supportive care","primary palliative care","hematopoietic cell transplantation","2026-04-21",{"date":128,"type":51},"2026-04-24",{"date":130,"type":51},"2026-01-05",{"date":132,"type":22},"2027-03-30",{"name":134,"class":58},"Massachusetts General Hospital",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":143,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":146,"briefSummary":147,"conditions":148,"keywords":151,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":59},"100292990","cognitive-training-intervention-and-attitudes-towards-genetics-100292990","NCT03094026","Cognitive Training Intervention and Attitudes Towards Genetics","Intervention Strategies to Improve Cognitive Functioning in Hematologic Cancer Survivors After Hematopoietic Cell Transplantation","cTAG","Inclusion Criteria:\n\n* ≥ 21 years old at time of allogeneic HCT performed at UAB\n* Outpatient and between 3 and 6 months post HCT\n* English speaking\n* Possess access to an internet-connected home computer\n\nExclusion criteria:\n\n* History of pre-existing neurological disorder or documented major psychiatric disorder; significant auditory, visual, or motor impairments\n* Participated in neuropsychological intervention within the past 6 months\n* History of color blindness","21 Years",{"count":145,"type":22},60,[25],"A pilot study to evaluate feasibility of enrollment of patients in an intervention to improve neurocognitive function in hematopoietic cell transplantation (HCT) survivors using the cognitive training Lumosity program. In addition, patients' interest in receiving information regarding genetic risk of cognitive impairment post-HCT will be measured.",[149,150,28],"Cognitive Impairment","Hematologic Neoplasms",[152,153,154,155,156,157],"Hematologic cancers","Hematopoietic cell transplantation","cognitive training","genetic knowledge","genetic attitude","adult cancer survivors","2026-04-16",{"date":160,"type":51},"2026-04-20",{"date":162,"type":51},"2017-08-21",{"date":164,"type":22},"2027-07",{"name":166,"class":58},"University of Alabama at Birmingham",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":92,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":23,"phases":176,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":59},"100579784","phase-2-early-use-of-tacrolimus-in-hla-mismatched-haploidentical-allogeneic-hematopoietic-transplantation-with-post-transplant-cyclophosphamide-100579784","NCT06828796","Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide","Inclusion Criteria:\n\n* Availability of a 5\u002F10-8\u002F10 mismatched (HLA-A, B, DR) haploidentical related donor with a negative HLA cross-match in the host vs. graft direction and willing to provide peripheral blood stem cells\n* Karnofsky status \\>\u002F= 70%\n* Hematologic malignancy requiring allogeneic transplantation\n* First allogeneic transplant only. Prior autologous transplant is allowed.\n\nExclusion Criteria:\n\n* Poor cardiac function: LVEF \\\u003C40%\n* Poor pulmonary function: FEV1 and FVC \\\u003C50% predicted\n* Poor liver function: bilirubin \\>\u002F= 3mg\u002FdL (not due to hemolysis, Gilbert's or primary malignancy)\n* Poor renal function: Creatinine \\>\u002F= 2mg\u002FdL or creatinine clearance (calculated or measured creatinine clearance is permitted) \\\u003C40mL\u002Fmin based on Traditional Cockcroft-Gault formula\n* Women of childbearing potential who currently are pregnant or who are not practicing adequate contraception\n* Patients who have any debilitating medical or psychiatric illness that would preclude their giving informed consent or their receiving optimal treatment and follow up","80 Years",{"count":175,"type":22},20,[177],"PHASE2","To evalute the safety and efficacy in reducing Cytokine Release Syndrome after hematopoietic stem cell transplantation by introducing immunosuppression earlier in the transplant process",[180,28],"Hematologic Disease and Disorders","2026-04-15",{"date":158,"type":51},{"date":184,"type":51},"2025-07-03",{"date":186,"type":22},"2028-06-30",{"name":188,"class":58},"Northside Hospital, Inc.",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":92,"enrollmentInfo":195,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":210},"100481537","multi-center-molecular-diagnosis-and-host-response-of-respiratory-viral-infections-in-pediatric-transplant-recipients-100481537","NCT05550298","Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients","Recipient Inclusion Criteria\n\n* Less than 18 years at the time of anticipated transplant\n* Participant meets one of the following criteria:\n\n  1. scheduled to receive allogeneic hematopoietic cell transplant within 14 days of enrollment or\n  2. Scheduled to or received solid organ transplant within 7 days before or after enrollment\n* Participant is receiving care at the time of enrollment at one of the study participating institutions.\n* Parent\u002Fguardian willing and able to provide informed consent, and if appropriate, child willing and able to provide informed assent.\n\nDonor Inclusion Criteria\n\n* Donor for HCT recipient enrolled on the VIPER study.\n* Willing and able to provide informed consent.\n\nExclusion Criteria:\n\nRecipient Exclusion Criteria\n\nNone\n\nDonor Exclusion Criteria\n\n* Is not an HCT donor for a participant enrolled on the VIPER study.\n* Not available to provide pre-transplant research blood sample.",{"count":196,"type":22},2000,"The participants are being asked to take part in this clinical trial, a type of research study, because the participants are scheduled to receive or have recently received a hematopoietic cell transplant (HCT) or a solid organ transplant (SOT).\n\nPrimary Objective\n\nTo determine if pre-transplant screening for respiratory viral load predicts RVI within 1- year post-transplant among survivors.\n\nSecondary Objectives:\n\n* To develop and validate a classifier based on pre-transplant immunological profile predictive of developing an acute respiratory viral infection (aRVI), with RSV\u002FPIV3\u002FHMPV\u002FSARS-CoV-2 through one-year post-transplant among survivors.\n* To develop and validate a classifier based on Day +100 post-transplant immunological profiles predictive of developing an acute respiratory viral infection (aRVI),with RSV\u002FPIV3\u002FHMPV\u002FSARS-CoV-2 through one-year post-transplant among survivors .",[28,199,200],"Solid Organ Transplant","Respiratory Viral Infection","2025-09-29",{"date":203,"type":51},"2025-10-02",{"date":205,"type":51},"2022-12-13",{"date":207,"type":22},"2029-08",{"name":209,"class":58},"Arkansas Children's Hospital Research Institute",27,{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":17,"minAge":218,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":23,"phases":221,"briefSummary":222,"conditions":223,"keywords":224,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":59},"100511786","virtual-rehabilitation-in-hct-100511786","NCT05943964","Virtual Rehabilitation in HCT","A Pilot Study of Virtual Rehabilitation After Hematopoietic Cell Transplantation","Inclusion Criteria:\n\n* Recipients between the ages of 8 and 23 years ≥100 days post allogeneic HCT.\n* Patients 8-14 years old should have a caregiver willing to assist with the implementation of the exercises during the session\n* Patients should have access to devices and a reliable internet connection.\n* Patients should be cleared for exercise by their physician\n* Patients are eligible to participate regardless of underlying diagnosis, preparative regimen, or graft source.\n\nExclusion Criteria:\n\n* Any physical impediment to exercise as evaluated by the treating physician.\n* Non-English-speaking patients (due to a lack of available interpreters through the telemedicine platform).","8 Years","23 Years",{"count":116,"type":22},[25],"Chronic GVHD (cGVHD) is a major cause of illness in patients who undergo hematopoietic transplantation (HCT). GVHD can affect any organ in the body, can require several years of treatment, and can impact the quality of life (QoL). Physical activity and exercise have been shown to enhance fitness and improve QoL in chronic illnesses including GVHD, however, patients often have barriers to attending sessions including distance, risk of infection, and physical therapists' lack of experience with pediatric patients. The team's goal is to assess whether a virtual rehabilitation program in children post-HCT (including children with chronic GVHD) is feasible and whether its implementation will improve physical functioning and QoL. Patients between the ages of 8 and 23 years who are at least one hundred days post-HCT will be eligible for participation. Patients will have an assessment by a pediatric physical therapist at the time of study entry, at the end of the rehabilitation program, and approximately 3 months later. They will be supplied with some exercise equipment (such as dumbbells and resistance bands). Patients will have twice weekly half-hour one-on-one online sessions with the physical therapist for 12 weeks. Patients will be recruited through the bone marrow transplant clinic.",[28],[225,226,227],"Virtual Rehabilitation","Virtual Exercise","Physical fitness","2025-09-15",{"date":230,"type":51},"2025-09-19",{"date":232,"type":51},"2023-07-31",{"date":234,"type":22},"2027-08",{"name":236,"class":58},"Emory University"]